论文部分内容阅读
目的与方法 :为探Wilms瘤中 p16基因表达与肿瘤病理分型和临床分期之间的关系 ,应用免疫组织化学SP方法 ,对 5 2例Wilms瘤及 7例肿瘤周围正常肾组织 (对照 )手术标本中 p16基因的表达情况进行检测。结果 :5 2例wilms瘤中有 16例 p16基因表达阳性 ,阳性率为 30 .8% ,其中预后良好型 p16基因表达阳性率为 37.2 % (16 /4 3) ,预后差者为 0 % (0 /9) ,均明显低于正常对照 10 0 % (7/7) ,差异具有显著的统计学意义 (P <0 .0 5 )。在Ⅰ、Ⅱ、Ⅲ、Ⅳ临床期中 ,p16表达阳性率以Ⅰ期最高 ,逐步递减 ,分别为 47.6 % (10 /2 1)、37.5 % (3/8)、2 8.6 % (2 /7)、6 .3% (1/16 )。结论 :Wilms瘤中 p16基因表达与肿瘤病理分型和临床分期存在联系 ,p16基因失活似是Wilms瘤发生发展中的晚期事件。
Aims and methods: To explore the relationship between p16 gene expression in Wilms’ tumor and pathological type and clinical stage of tumor, and apply immunohistochemical SP method to treat 52 Wilms tumors and 7 cases of tumor surrounding normal kidney tissue (control) The expression of p16 gene in the specimens was examined. RESULTS: Of the 52 Wilms tumors, 16 were positive for p16 gene expression, with a positive rate of 30.8%. The positive rate of positive p16 gene expression was 37.2% (16/43), and the poor prognosis was 0% ( 0 / 9), were significantly lower than the normal control 10% (7/7), the difference was statistically significant (P <0. 05). In the clinical stages I, II, III, and IV, the positive rate of p16 expression was the highest in stage I and gradually decreased, with 47.6 % (10 /21), 37.5 % (3/8), and 28.6 % (2 /7) respectively. , 6.3% (1/16). Conclusion: The expression of p16 gene in Wilms tumor is related to the pathological type and clinical stage of tumor. Inactivation of p16 gene seems to be a late event in the development of Wilms tumor.